LTFS
VIRX

Ladenburg Thalmann Financial Services’s Viracta Therapeutics, Inc. Common Stock VIRX Stock Holding History

Ladenburg Thalmann Financial Services’s Portfolio VIRX Stock Details VIRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-1
Closed – – 5345
2018
Q2 		$0 Hold
1
– – ﹤0.01% 5166
2018
Q1 		$0 Hold
1
– – ﹤0.01% 5224
2017
Q4 		$0 Buy
+1
New +$94 ﹤0.01% 5139
2017
Q2 		– Hold
0
– – – 4989
2017
Q1 		– Hold
0
– – – 4989
2016
Q4 		– Hold
0
– – – 4970
2016
Q3 		– Sell
-3
Closed – – 4890
2016
Q2 		$0 Hold
3
– – ﹤0.01% 4859
2016
Q1 		$0 Hold
3
– – ﹤0.01% 4828
2015
Q4 		$1K Hold
3
– – ﹤0.01% 4559
2015
Q3 		$1K Buy
3
+2
+200% +$722 ﹤0.01% 4471
2015
Q2 		$1K Hold
1
– – ﹤0.01% 4542
2015
Q1 		$1K Hold
1
– – ﹤0.01% 4463
2014
Q4 		$1K Buy
+1
New +$451 ﹤0.01% 4253

Other funds holding VIRX

EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
RPAM
Rhenman & Partners Asset Management Stockholm, Sweden $810M AUM 30.2% 1-Year Est. Return

Ladenburg Thalmann Financial Services's VIRX Position: Q3 2018 in Review

Ladenburg Thalmann Financial Services sold out of Viracta Therapeutics, Inc. Common Stock (VIRX) in Q3 2018, closing a stake of 1 share.

Ladenburg Thalmann Financial Services first reported a position in VIRX in Q4 2014 and held it in 10 quarters. The position peaked at $1K in Q4 2015. 48 funds tracked by Wall St. Rank hold VIRX as of Q3 2018.

  • Ladenburg Thalmann Financial Services reported no remaining Viracta Therapeutics, Inc. Common Stock position as of Q3 2018 after selling out during the quarter.
  • Ladenburg Thalmann Financial Services sold 1 Viracta Therapeutics, Inc. Common Stock share in Q3 2018.
  • Ladenburg Thalmann Financial Services first reported a position in Viracta Therapeutics, Inc. Common Stock in Q4 2014 and held it in 10 quarters.
  • Ladenburg Thalmann Financial Services's Viracta Therapeutics, Inc. Common Stock position peaked at $1K in Q4 2015.
  • 48 funds tracked by Wall St. Rank held Viracta Therapeutics, Inc. Common Stock as of Q3 2018.

Based on Ladenburg Thalmann Financial Services's 13F filing for Q3 2018, filed 14 Nov 2018.